Insulin, glucagon-like peptide 1, glucose-dependent insulinotropic polypeptide and insulin-like growth factor I as putative mediators of the hypolipidemic effect of oligofructose in rats

被引:88
|
作者
Kok, NN
Morgan, LM
Williams, CM
Roberfroid, MB
Thissen, JP
Delzenne, NM [1 ]
机构
[1] Univ Catholique Louvain, Unite Biochim Toxicol & Cancerol, Dept Pharmaceut Sci, B-1200 Brussels, Belgium
[2] Univ Catholique Louvain, Unite Diabetol & Nutr, Dept Med Interne, B-1200 Brussels, Belgium
[3] Univ Surrey, Sch Biol Sci, Guildford GU2 5XH, Surrey, England
[4] Univ Reading, Hugh Sinclair Unit Human Nutr, Reading RG6 6AP, Berks, England
来源
JOURNAL OF NUTRITION | 1998年 / 128卷 / 07期
关键词
oligofructose; triglycerides; insulin; incretins; rats;
D O I
10.1093/jn/128.7.1099
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
The addition of oligofructose as a dietary fiber decreases the serum concentration and the hepatic release of VLDL-triglycerides in rats. Because glucose, insulin, insulin-like growth factor I (IGF-I) and gut peptides [i.e., glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1)]) are factors involved in the metabolic response to nutrients, this paper analyzes their putative role in the hypolipidemic effect of oligofructose. Male Wistar rats were fed a nonpurified diet with or without 10% oligofructose for 30 d. Glucose, insulin, IGF-I and GIP concentrations were measured in the serum of rats after eating. GIP and GLP-1 contents were also assayed in small intestine and cecal extracts, respectively. A glucose tolerance test was performed in food-deprived rats, Serum insulin level was significantly lower in oligofructose-fed rats both after eating and in the glucose tolerance test, whereas glycemia was lower only in the postprandial state. IGF-I serum level did not differ between groups. GIP concentration was significantly higher in the serum of oligofructose-fed rats. The GLP-1 cecal pool was also significantly higher. In this study, we have shown that cecal proliferation induced by oligofructose leads to an increase in GLP-1 concentration. This latter incretin could be involved in the maintenance of glycemia despite a lower insulinemia in the glucose tolerance test in oligofructose-fed rats. We discuss also the role of hormonal changes in the antilipogenic effect of oligofructose.
引用
收藏
页码:1099 / 1103
页数:5
相关论文
共 50 条
  • [21] Practical guide: Glucagon-like peptide-1 and dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonists in diabetes mellitus
    Alqifari, Saleh Fahad
    Alkomi, Omar
    Esmail, Abdullah
    Alkhawami, Khadijeh
    Yousri, Shahd
    Muqresh, Mohamad Ayham
    Alharbi, Nawwarah
    Khojah, Abdullah A.
    Aljabri, Ahmed
    Allahham, Abdulrahman
    Prabahar, Kousalya
    Alshareef, Hanan
    Aldhaeefi, Mohammed
    Alrasheed, Tariq
    Alrabiah, Ali
    Albishi, Laila A.
    WORLD JOURNAL OF DIABETES, 2024, 15 (03)
  • [22] Incretin physiology beyond glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: cholecystokinin and gastrin peptides
    Rehfeld, J. F.
    ACTA PHYSIOLOGICA, 2011, 201 (04) : 405 - 411
  • [23] Clinical Significance of Autoantibody Measurement for Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 in the Plasma
    Yamagata, Hiroki
    Onishi, Shunichiro
    Yoshida, Tomohiko
    Hiwasa, Takaki
    Takemoto, Minoru
    DIABETES, 2022, 71
  • [24] Turner's Syndrome, Glucagon-like Peptide 1, and Glucose-dependent Insulinotropic Polypeptide Agents: Silver Bullets?
    Glueck, Charles J.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2024,
  • [25] Measurement of the incretin hormones: glucagon-like peptide-1 and glucose-dependent insulinotropic peptide
    Kuhre, Rune Ehrenreich
    Albrechtsen, Nicolai Jacob Wewer
    Hartmann, Bolette
    Deacon, Carolyn F.
    Hoist, Jens Juul
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2015, 29 (03) : 445 - 450
  • [26] Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 do not account for the entire incretin effect in healthy humans
    Veedfald, S.
    Sun, Y.
    Xiang, C.
    Xie, C.
    Wu, T.
    Bound, M.
    Grivell, J.
    Hartmann, B.
    Jones, K.
    Horowitz, M.
    Holst, J. J.
    Rayner, C. K.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S48 - S48
  • [27] Glucagon-like peptide-2, but not glucose-dependent insulinotropic polypeptide, stimulates glucagon release in patients with type 1 diabetes
    Christensen, Mikkel
    Knop, Filip K.
    Vilsboll, Tina
    Aaboe, Kasper
    Holst, Jens J.
    Madsbad, Sten
    Krarup, Thure
    REGULATORY PEPTIDES, 2010, 163 (1-3) : 96 - 101
  • [28] Brain insulin, insulin-like growth factor 1 and glucagon-like peptide 1 signalling in Alzheimer's disease
    Ferreira, Sergio T.
    JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 (04)
  • [29] CELL AND MOLECULAR-BIOLOGY OF THE INCRETIN HORMONES GLUCAGON-LIKE PEPTIDE-I AND GLUCOSE-DEPENDENT INSULIN RELEASING POLYPEPTIDE
    FEHMANN, HC
    GOKE, R
    GOKE, B
    ENDOCRINE REVIEWS, 1995, 16 (03) : 390 - 410
  • [30] Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals
    Gasbjerg, Laerke S.
    Helsted, Mads M.
    Hartmann, Bolette
    Jensen, Mette H.
    Gabe, Maria B. N.
    Sparre-Ulrich, Alexander H.
    Veedfald, Simon
    Stensen, Signe
    Lanng, Amalie R.
    Bergmann, Natasha C.
    Christensen, Mikkel B.
    Vilsboll, Tina
    Holst, Jens J.
    Rosenkilde, Mette M.
    Knop, Filip K.
    DIABETES, 2019, 68 (05) : 906 - 917